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Extremely low frequency electromagnetic 
field enhances human keratinocyte cell 
growth and decreases proinflammatory 
chemokine production
Electromagnetic fields (EMF) can 
exert biological effects and have 
been used in clinical practice to 
promote regeneration processes 
as in the treatment of chronic 
ulcers. Vianale et al. have stud-
ied the effect of EMF on kerati-
nocyte proliferation and che-
mokine production in an in 
vitro model. Gene expression 
and release of RANTES, MCP-1, 
MIP-1α, and IL-8 were signifi-
cantly reduced after exposure to EMF. Keratinocyte proliferation 
was enhanced, while NF-κB levels were undetectable after long 
(> 72 h) exposure to EMF, thus being inversely correlated with 
cell density. These results suggest that effects on tissue inflam-
mation and regeneration by EMF may be mediated through the 
modulation of chemokines and NF-κB downregulation. Br J 
Dermatol 2008; 158:1189–96.
Pentaherbs suppresses atopic dermatitis-
related inflammatory mediators
Traditional Chinese medicine is a widely used alternative 
therapy for atopic dermatitis (AD). However, data regarding its 
immunomodulatory properties are lacking. In cultured circu-
lating mononuclear cells from healthy blood donors, a novel 
Pentaherbs concoction formulated from five herbs was able 
to suppress several inflammatory mediators, including BDNF, 
TARC, TNF-α, and IFN-γ at both 
RNA and protein levels. In an 
open-label clinical trial, plasma 
BDNF and TARC concentrations 
in 28 children with AD were 
also lower following a 3-month 
Pentaherbs treatment. These find-
ings suggest that Pentaherbs pos-
sesses in vitro and in vivo immu-
nomodulatory properties that may 
mediate its clinical efficacy in AD 
treatment. Br J Dermatol 2008; 
158:1216–23.
Skin pathogenesis in crusted (Norwegian) scabies
Crusted scabies is a rare and severely debilitating disease charac-
terized by infestation of the skin with up to millions of Sarcoptes 
scabiei mites, high total IgG levels, extremely high total IgE 
levels, and the development of hyperkeratotic skin crusts. 
Immunohistochemical analysis 
reveals skin-homing cytotoxic 
T cells as the predominant 
lymphoid cells in the dermis of 
crusted scabietic lesions, along 
with the inflammatory cytokine 
IL-1β and the anti-inflammatory 
cytokine TGF-β1. Analogous to 
psoriasis, activated CD8+ T cells in crusted scabies lesions may 
induce dysregulated keratinocyte apoptosis contributing to the 
elicitation and progress of epidermal hyperproliferation. Br J 
Dermatol 2008; 158:1247–55.
MUM1 is a valuable tool for the distinction 
of lymphomatoid papulosis and primary 
cutaneous anaplastic large-cell lymphoma
Cutaneous CD30+ lymphoproliferative disorders show over-
lapping clinical and histological features but differ significantly 
in their prognosis and require different treatment. Thus there is 
a need for phenotypic markers to distinguish these diseases. 
Kempf et al. studied the expression of MUM1/IRF4 in CD30+ 
lymphomas of the skin. MUM1 was strongly expressed in the 
majority of cases of lymphomatoid papulosis (LyP) (85%). In 
contrast to LyP and cutaneous infiltrates of systemic anaplas-
tic large T-cell lymphoma (ALCL), only 20% of primary cuta-
neous ALCL cases were positive for MUM1. The differential 
expression of MUM1 renders it a novel adjunctive diagnostic 
marker in CD30+ lymphoproliferative disorders and underlines 
the unique biology of primary cutaneous ALCL. Br J Dermatol 
2008; 158:1280–7.
Combining etanercept and acitretin in the 
therapy of chronic plaque psoriasis: a 24-week, 
randomized, controlled, investigator-blinded 
pilot trial
Combining the new 
biologic agents with 
traditional treatments 
will offer dermatol- 
ogists new strategies 
for the long-term con 
trol of psoriasis. This 
study shows that the combined treatment, i.e. acitretin 0.4 
mg kg-1 daily and etanercept 25 mg weekly, is as effective as 
etanercept 25 mg twice weekly and significantly more effec-
tive than acitretin 0.4 mg kg-1 daily monotherapy. In particular, 
PASI 75 response rate at week 24 for the combined treatment 
was 45.9%. The combined treatment was not associated with 
significant alterations in aspartate aminotransferase, alanine 
aminotransferase, cholesterol, or triglycerides. The low dose of 
etanercept used could significantly reduce the cost of the treat-
ment. Br J Dermatol 2008; 158:1345–9.
